- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01898078
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas
Study Overview
Detailed Description
The drug being tested in this study is called alisertib. Alisertib is being tested in adult participants with advanced solid tumors or lymphomas.
The study enrolled 26 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
- Alisertib 50 mg Fed + Fasted
- Alisertib 50 mg Fasted + Fed
All participants will be asked to take one alisertib tablet (ECT), orally, with or without a standard high-fat breakfast Cycle 1, Day 1, with the respective alternate food intake condition (fasted to fed or fed to fasted) on Cycle 2, Day 1, each followed by 14-day rest period. Participants will take alisertib, ECT, orally BID on Days 4 to 10 of Cycles 1 and 2, each followed by 14-day rest period. From Cycle 3 onwards participants will continue taking alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity.
This multi-center trial conducted at 3 sites in the United States. Participants will make multiple visits to the clinic and plus a final visit after 30 days of receiving their last dose of drug for a follow-up assessment.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Bronx, New York, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
San Antonio, Texas, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Histologically or cytologically confirmed advanced tumors or lymphomas for which standard curative or life-prolonging treatment does not exist, or is no longer effective or tolerable
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Participant must meet protocol-specified laboratory values
- Suitable venous access
- Female participants who are postmenopausal for at least 1 year OR are surgically sterile OR if of childbearing potential, agree to practice 2 effective methods of contraception at the same time or agree to practice true abstinence
- Male participants who agree to practice effective barrier contraception during the entire study and through 4 months after the last dose of study drug OR agree to practice true abstinence
Exclusion Criteria:
- Prior or current investigational therapies within 4 weeks before the first dose of alisertib
- Female participants who are lactating or pregnant
- Participant requiring treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine, or phenobarbital, or rifampin, rifabutin, rifapentine, or St. John's wort within 14 days before the first dose of alisertib and during the study
- Medical conditions requiring daily, chronic, or regular use of proton pump inhibitors (PPIs) within 7 days preceding the first dose of alisertib, or histamine (H2)-receptor antagonists
- Participant requiring systemic anticoagulation
- Ongoing nausea or vomiting that is Grade 2 or worse in intensity
- Known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption, excretion, or tolerance of alisertib
- History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness such as severe chronic obstructive pulmonary disease
- Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
- Participant who are lactose-intolerant or are unwilling/unable to consume the protocol specified standardized high-fat breakfast
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Alisertib 50 mg Fed + Fasted
Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, twice daily (BID) on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
|
Alisertib ECT
Other Names:
|
EXPERIMENTAL: Alisertib 50 mg Fasted + Fed
Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
|
Alisertib ECT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax: Maximum Observed Plasma Concentration of Alisertib
Time Frame: Cycles 1 and 2, Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
|
Cycles 1 and 2, Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
|
AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib
Time Frame: Cycles 1 and 2, Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
|
Cycles 1 and 2, Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
|
AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib
Time Frame: Cycles 1 and 2, Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
|
Cycles 1 and 2, Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From first dose through 30 days after the last dose of study drug (up to 225 days)
|
An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. |
From first dose through 30 days after the last dose of study drug (up to 225 days)
|
Number of Participants With Clinically Significant Change in Laboratory Parameters Reported as AEs
Time Frame: From first dose through 30 days after the last dose of study drug (up to 225 days)
|
The number of participants with any clinical significant change in safety laboratory values collected throughout the study.
|
From first dose through 30 days after the last dose of study drug (up to 225 days)
|
Number of Participants With Clinically Significant Change in Vital Sign Reported as AEs
Time Frame: From first dose through 30 days after the last dose of study drug (up to 225 days)
|
The number of participants with any clinical significant change in vital signs (sitting diastolic and systolic blood pressure, heart rate, and temperature) were collected throughout the study.
|
From first dose through 30 days after the last dose of study drug (up to 225 days)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C14017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditionsUnited States
-
BioNova Pharmaceuticals (Shanghai) LTD.TerminatedFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell LymphomaChina
-
Tessa TherapeuticsActive, not recruitingAnaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)United States
-
Royal Marsden NHS Foundation TrustUnknownMantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)United Kingdom
-
AmgenCompletedLymphoma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Low Grade Lymphoma
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
-
Reid Merryman, MDGenentech, Inc.RecruitingFollicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-hodgkin LymphomaUnited States
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Merck Sharp & Dohme LLCTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone LymphomaAustralia
Clinical Trials on Alisertib
-
Millennium Pharmaceuticals, Inc.CompletedOvarian CarcinomaUnited States
-
Millennium Pharmaceuticals, Inc.Completed
-
M.D. Anderson Cancer CenterMillennium Pharmaceuticals, Inc.CompletedLung Cancer | MesotheliomaUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors | LymphomasSingapore
-
The University of Texas Health Science Center at...No longer availableProstate Cancer
-
Millennium Pharmaceuticals, Inc.CompletedSmall Cell Lung Cancer | Non-Small Cell Lung Cancer | Metastatic Breast Cancer | Head and Neck Squamous Cell Carcinoma | Gastroesophageal Adenocarcinoma | Advanced Nonhematological MalignanciesUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedNeuroblastoma | Unspecified Childhood Solid Tumor, Excluding CNS
-
Millennium Pharmaceuticals, Inc.WithdrawnAdvanced Nonhematologic MalignanciesUnited States
-
Millennium Pharmaceuticals, Inc.CompletedLymphoma | Advanced Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedMultiple Myeloma | Waldenstrom's Macroglobulinemia | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B-cell Lymphoma | B-Cell Chronic Lymphocytic Leukemia | Enteropathy Associated T-cell Lymphoma | B-cell Follicular Lymphoma | B-cell Marginal Zone Lymphoma | B-cell Mantle... and other conditionsUnited States